Most subjects were satisfied or very satisfied with treatment at Week 16.
EDEN Study Treatment Results
Select a skin type for individual treatment results
Age: 17 | Gender: Female
Compared against baseline
EDEN Study Design
EDEN was an open-label interventional study (N=50) conducted in 3 countries (Mauritius, Singapore, and USA) in subjects of Asian (n=20), Latin-American (n=17), or black/African-American (n=13) ethnicity, with an Investigator’s Global Assessment (IGA) of moderate or severe facial acne (enrollment 2:1), and Fitzpatrick skin type (FST) IV to VI. 74% and 22% of patients had FST IV and V, respectively, whereas 70% and 30% of patients had moderate (IGA 3) and severe (IGA 4) acne, respectively. For 16 weeks, subjects applied 0.3% Adapalene/BPO (once daily) and utilized a skin care regimen (oil control foam wash and oil control moisturizer SPF30). Primary efficacy endpoint: Patient-reported outcomes (PROs) at Week 12 and 16/early termination as measured by Dermatology Life Quality Index (DLQI)/ Children’s DLQI* and patient satisfaction over time and by ethnic population. Other assessments included IGA, Investigator’s Global Assessment of Improvement (GAI), and safety.5